Company Description
Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers.
The company’s product candidates include ADG106, a human ligand-blocking agonistic anti- CD137 IgG4 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a masked fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase 1b/2 clinical development for the treatment of advanced/metastatic solid tumors.
It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a v POWERbody, which is in preclinical stage for the treatment off-tumor toxicities, as well as develops anti-CD28 bispecific POWERbody TCEs.
The company was incorporated in 2011 and is headquartered in Suzhou, China.
| Country | China |
| Founded | 2011 |
| IPO Date | Feb 9, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 174 |
| CEO | Peter P. Luo |
Contact Details
Address: Building C14, 4th Floor Suzhou, 215123 China | |
| Phone | 86 512 8777 3632 |
| Website | adagene.com |
Stock Details
| Ticker Symbol | ADAG |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $19.00 |
| CIK Code | 0001818838 |
| CUSIP Number | 005329107 |
| ISIN Number | US0053291078 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Peter P. Luo Ph.D. | Co- Founder, Chairman, Chief Executive Officer and President of Research & Development |
| Man Kin Tam M.B.A. | Chief Financial Officer and Director |
| Dr. Jc Xu M.D., Ph.D. | Chief Scientific Officer |
| Ami Celeste Knoefler | Vice President of Investor Relations and Corporate Communications |
| Ling Zhou | Head of Human Resources |
| Dr. Qinghai Zhao | Chief Manufacturing Officer |
| Yan Li M.B.A. | Senior Vice President of Bioinformatics and Information Technology |
| Xiaohong She | Senior Vice President and Head of Clinical Operations |
| Dr. Guizhong Liu Ph.D. | Senior Vice President of Early Drug Discovery |
| Alexander Goergen | Vice President and Head of Business Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 7, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 7, 2024 | 6-K/A | Filing |
| Nov 7, 2024 | 6-K/A | Filing |
| Nov 7, 2024 | 6-K | Report of foreign issuer |
| Sep 24, 2024 | SCHEDULE 13G | Filing |
| Sep 16, 2024 | 6-K | Report of foreign issuer |
| Jul 25, 2024 | 6-K | Report of foreign issuer |
| Mar 29, 2024 | 6-K | Report of foreign issuer |
| Mar 29, 2024 | 424B5 | Filing |
| Mar 29, 2024 | 20-F | Annual and transition report of foreign private issuers |